• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Accelovance acquires CRO Radiant Development

Accelovance acquires CRO Radiant Development

March 7, 2013
CenterWatch Staff

Rockville, Md.-based CRO  Accelovance has announced the acquisition of Radiant Development, the CRO division of Radiant Research. Terms of the transaction were not disclosed. 

Accelovance, a patient-centric CRO, has seen much of its growth in the vaccine, infectious disease and oncology markets. The addition of Radiant Development broadens Accelovance's ability across a range of therapeutic areas. Radiant Development has performed studies in areas including cardiovascular, men's and women's health, rheumatology, dermatology, oncology and medical device, and also has specialized expertise in consumer health and nutrition.

"We are thrilled to have 100% of the Radiant team led by Vita Lanoce as part of our company," said Stephen J. Trevisan, Accelovance president and CEO.

Operating out of locations in Stuart, Florida; Chicago; and Durham, N.C., Radiant Development is a full-service CRO that has managed over 200 research studies since its inception, and has established strategic partnerships in Europe and Asia.

Radiant Development will operate as a division of Accelovance, providing project management and clinical monitoring, medical, safety and pharmacovigilance, regulatory consulting, medical writing, data management and statistical services.

Current customers, employees and stakeholders of Radiant Development will receive its ongoing, preferred provider relationship with the Radiant Research and Clinical Research Advantage site network.     

Accelovance offers full CRO, clinical sites, patient recruitment and call center services, and has a 100% owned subsidiary providing CRO services in China.  It also has six wholly-owned, research-dedicated clinical sites.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing